GLP-1 Weight-Loss Drugs Show Remarkable Promise in Fighting Addiction, Large Veterans Study Finds

Medications originally designed to treat diabetes and obesity may hold the key to addressing America's addiction crisis. A groundbreaking study of more than 600,000 U.S. veterans published today in The BMJ reveals that GLP-1 receptor agonists—drugs like semaglutide (Ozempic, Wegovy), liraglutide, and dulaglutide—are associated with significantly lower risks of developing substance use disorders across virtually every major addictive substance.

The research, conducted by investigators at Washington University School of Medicine in St. Louis and the VA Saint Louis Health Care System, represents one of the largest and most comprehensive examinations of metabolic medications' effects on addiction to date. Its findings suggest these widely prescribed drugs may work not by targeting specific substances, but by dampening the fundamental biological mechanisms that drive craving itself.

A Cross-Substance Protective Effect

The study analyzed electronic health records from 606,434 veterans with type 2 diabetes over a three-year period. Participants were divided into two groups: those without existing substance use disorders at baseline and those already living with diagnosed addiction.

Among the 524,817 participants without prior substance use disorders, GLP-1 users showed a 14% lower risk of developing any addiction compared to patients taking non-GLP-1 diabetes medications. The protective effect spanned every substance category examined:

• Opioids: 25% reduction in new opioid use disorders
• Cocaine: 20% reduction in new cocaine use disorders
• Nicotine: 20% reduction in new tobacco use disorders
• Alcohol: 18% reduction in new alcohol use disorders
• Cannabis: 14% reduction in new cannabis use disorders

"In addiction medicine, most treatments target just one thing—a nicotine patch helps with smoking, but not alcohol," explained senior author Dr. Ziyad Al-Aly, a clinical epidemiologist at WashU Medicine and Chief of Research and Development at the VA Saint Louis Health Care System. "There's no medication that works across addictive substances, let alone all of them."

The revelation, according to Al-Aly, is that GLP-1 medications appear to work uniformly against all major substances—not because they act against alcohol or opioids or nicotine specifically, but because they likely act against the craving itself. "It blunts that craving that pulls people toward whatever they're addicted to."

Dramatic Reductions in Overdose and Death

For the 81,617 participants who entered the study with existing substance use disorders, the benefits were even more pronounced. After three years of follow-up, GLP-1 users experienced:

• 50% reduction in drug-related deaths
• 40% reduction in overdoses
• 30% reduction in emergency department visits
• 25% reduction in hospitalizations

The researchers estimated that GLP-1 use was associated with 12 fewer serious addiction-related events per 1,000 users—a substantial public health impact given that millions of Americans already take these medications.

From "Food Noise" to "Drug Noise"

The study's conceptual framework draws on a phenomenon many GLP-1 users have described: the quieting of "food noise," the persistent mental preoccupation with eating that drives overconsumption. Al-Aly suggests the medications may achieve similar effects on what he terms "drug noise"—the relentless craving that characterizes addiction across substances.

This interpretation aligns with emerging neurobiological evidence. GLP-1 receptors are present in brain regions involved in reward processing, including the central amygdala and other areas that regulate hedonic feeding and addictive behaviors. By modulating activity in these circuits, GLP-1 drugs may interrupt the core reinforcement cycles that drive compulsive substance use.

Previous research from the National Institutes of Health has demonstrated that GLP-1 medications can penetrate deep into brain tissue, reaching areas responsible for reward and craving. The current findings suggest these mechanistic observations translate into clinically meaningful outcomes at the population level.

Implications for Treatment Gaps

The study's findings carry particular significance for substances lacking FDA-approved pharmacological treatments. Methamphetamine use disorder, for instance, currently has no approved medications—leaving patients dependent on behavioral interventions alone. The cross-substance activity of GLP-1 drugs raises the possibility of addressing this treatment gap.

For patients with diabetes or obesity who also struggle with substance use, the research suggests a potential dual benefit: one medication addressing both metabolic and addictive conditions simultaneously. Given the high comorbidity between metabolic disorders and addiction—often rooted in shared neurobiological pathways involving dopamine and reward processing—this overlap could affect substantial numbers of patients.

The Path Forward

The researchers emphasize that their observational findings, while compelling, require confirmation through randomized controlled trials specifically designed to test GLP-1 drugs as addiction treatments. Such trials would need to measure hard outcomes including overdose and drug-related death, outcomes that this study suggests are favorably affected.

Several clinical trials are already underway examining GLP-1 medications for alcohol use disorder and opioid use disorder. The current evidence provides strong rationale for expanding this research pipeline and potentially accelerating regulatory consideration.

If future studies confirm these effects, the public health implications could be transformative. With tens of millions of Americans already using GLP-1 medications and prescription rates continuing to climb, these drugs may already be exerting a population-level protective effect that has gone largely unrecognized.

A Fundamental Shift in Approach

Perhaps most profoundly, the research points toward a reconceptualization of addiction treatment. Rather than addressing one substance at a time—nicotine patches for smoking, naltrexone for alcohol, buprenorphine for opioids—GLP-1 medications may offer a pathway to targeting the shared biology underlying all addictive behaviors.

"Moving beyond food noise to drug noise, GLP-1s are quieting the roar of addiction," Al-Aly said. "That cross-substance signal points to a shared biology underlying addiction, and it opens the door to a fundamentally different approach: not treating one addiction at a time, but targeting that common biologic signal, that common craving across addictions."

For individuals struggling with substance use disorders, these findings suggest that emerging pharmacological options may soon expand beyond traditional medication-assisted treatments. While medication-assisted treatment remains the gold standard for opioid and alcohol use disorders specifically, the prospect of broad-spectrum anti-addiction medications represents a promising frontier in addiction medicine.

The study was funded by the U.S. Department of Veterans Affairs. The authors noted that the findings do not represent the views of the VA or the U.S. government.